Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Antibiotic (aminoglycoside)
Original Date: 
March 1992
Revised Date: 
December 2020
  • Gram (-) organisms resistant to other antibiotics
  • IV intermittent infusion: over 30 minutes

< 1.2 kg:

  • (0 - 4 weeks): 7.5 mg/kg/dose Q18-24H

1.2 - 2 kg:

  • (0 - 7 days): 7.5 mg/kg/dose Q12-18H
  • (> 7 days): 7.5 mg/kg/dose Q8-12H

> 2 kg:

  • (0 - 7 days): 10 mg/kg/dose Q12H
  • (> 7 days): 10 mg/kg/dose Q8H
Side Effects: 
  • Dermatologic: rash
  • Hematologic: anemia, eosinophilia, leukopenia
  • Neuromuscular & skeletal: increased neuromuscular blockade when used with other neuromuscular blocking agents
  • Otic: ototoxicity
  • Renal: nephrotoxicity
Parameters to Monitor: 
  • Renal: serum creatinine, urea, urine output
  • Therapeutic drug levels:
    • Trough (0 - 30 minutes before dose due): < 5 mg/L
    • Peak (30 minutes after the end of a 30 minutes infusion): 20 - 30 mg/L

** When checking level, administer next dose as scheduled. Do not wait for levels to be reported unless otherwise advised

Reconstitution and Stability: 


  • Amikacin 250 mg/mL
    • Take 1 mL (250 mg) and add to 24 mL D5W
    • Final concentration: 10 mg/mL


  • Amikacin 250 mg/mL
    • Take 1 mL (250 mg) and add to 49 mL D5W
    • Final concentration: 5 mg/mL

- Solutions Compatible: dextrose, 0.45% NaCl, 0.9% NaCl, dextrose-saline combinations

- Y-site Compatible: acyclovir, cloxacillin, dexmedetomidine, fluconazole, furosemide, hydromorphone, midazolam, morphine, piperacillin-tazobactam, vancomycin

Incompatible: amphotericin B, heparin

** Due to the potential inactivation of aminoglycosides and antibiotics such as penicillins and cephalosporins, it is preferable to separate administration of these antibiotics by 30 - 60 minutes


-Taketomo CK, Hodding JH, Kraus DM.  Pediatric Dosage Handbook 22nd Edition.  Hudson: Lexi-Comp Inc.;2015

- American Society on Health-System Pharmacists (ASHP).  Handbook on injectable Drugs. 19th Edition. Bethesda: ASHP 2017



The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.